Answers are grounded in this paper and cite their sources.
( Int J Obstet Anesth . 2025:64:104742. doi:10.1016/j.ijoa.2025.104742) Opioid use disorder (OUD) is a major global health concern, with increasing prevalence among pregnant individuals and substantial associated maternal morbidity and mortality. Pharmacologic maintenance therapy with methadone or buprenorphine is widely recommended during pregnancy and the postpartum period because it improves maternal outcomes and reduces mortality. However, effective postoperative pain management after cesarean delivery (CD) in patients receiving medications for opioid use disorder (MOUD) presents ongoing clinical challenges. These patients often report greater pain intensity and require higher doses of supplemental opioids compared with opioid-naive individuals. Existing studies evaluating post-CD opioid consumption in this population have produced inconsistent findings, largely due to variability in anesthetic techniques and inconsistent use of neuraxial opioids and multimodal analgesia.
No takes yet. Share an insight, caveat, or question.
Roy et al. (2026) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: